Meridian Bioscience Inc. (VIVO) News
Filter VIVO News Items
VIVO News Results
|Loading, please wait...|
VIVO News Highlights
- For VIVO, its 30 day story count is now at 14.
- Over the past 21 days, the trend for VIVO's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- The most mentioned tickers in articles about VIVO are JACK, DELL and EYE.
Latest VIVO News From Around the Web
Below are the latest news stories about Meridian Bioscience Inc that investors may wish to consider to help them evaluate VIVO as an investment opportunity.
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Andy Kitzmiller joined Meridian Bioscience as Executive Vice President and Chief Financial Officer, reporting directly to CEO Jack Kenny. He will oversee the global finance organization and financial activities, including accounting and controllership, financial planning and analysis, tax, internal audit, and treasury.
Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Magellan Diagnostics resumed manufacturing and distribution of their LeadCare® II test kits.
Meridian Bioscience (NASDAQ:VIVO) stock performs better than its underlying earnings growth over last five years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Meridian Bioscience (VIVO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Meridian Bioscience, Inc. (VIVO) Q1 2022 Earnings Conference Call February 4, 2022 10:00 A.M. ET Company Participants Charlie Wood - Vice President, Investor Relations Jack Kenny - Chief Executive Officer Julie Smith - Senior Vice President Controller & Principal Accounting Officer Conference Call Participants Yi Chen - H.C. Wainwright Presentation...
Meridian Bioscience <
View more earnings on VIVOSee more from BenzingaDelcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To LiverValneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 40% and 19.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2021.
Meridian Bioscience (NASDAQ:VIVO) is scheduled to announce Q1 earnings results on Friday, February 4th, before market open.The consensus EPS Estimate is $0.27 (-52.6% Y/Y) and the